Thursday 13 December 2018
Home      All news      Contact us      English
Hkej - 7 days ago

花旗:若全國推行帶量採購 中生製藥利潤將下挫26%

花旗   中國生物製藥(01177) 評級:買入 目標價:16元- gt;13.2元(較前收市價5.84元有1.26倍潛在升幅) 花旗發表報告,指中生製藥將是受「帶量採購」影...

全文:花旗:若全國推行帶量採購 中生製藥利潤將下挫26%


信報財經新聞有限公司版權所有,不得轉載。Copyright © 2018 Hong Kong Economic Journal Company Limited. All rights

Related news

Latest News
Hashtags:   

若全國推行帶量採購

 | 

中生製藥利潤將下挫26%

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Sources